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Abstract 
Protein aggregation and inclusion body formation are hallmarks of 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and 
amyotrophic lateral sclerosis (ALS). These neurodegenerative diseases share a common 
pathology in that all include accumulation of insoluble protein aggregates in the brain. 
TAR-DNA-binding protein (TDP-43) is the major component found in the pathological 
inclusions of two of these diseases, ALS and frontotemporal lobar degeneration with 
ubiquitin-positive inclusions (FTLD-U). This thesis focuses upon the biophysical basis 
for TDP-43 aggregation in S. cerevisiae.  Current in vitro evidence indicates that TDP-43 
is a natively dimeric protein and that binding to RNA inhibits aggregation. 
Corresponding genetic results in yeast in which specific components of the RNA-decay 
machinery have been knocked-out, indicate that the buildup of specific cellular RNAs is 
capable of counteracting TDP-43 aggregation and toxicity in vivo. This thesis provides 
evidence of separate pathologies of TDP-43 and TDP-43 mutants in S. Cerevisiae.  This 
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Chapter One: Introduction 
1.1 Overview: Protein Localization in Disease 
Eukaryotic cells contain organelles and a complex endomembrane system.  These 
organelles provide distinct compartments for different metabolic activities.  Protein 
translation occurs solely in the cytosol compartment of the cell.  Cells require 
translocation of proteins to exert protein function in different organelles.  Approximately 
half of the proteins generated by a cell are transported into or across one or more cellular 
membranes to reach their functional location (Chacinska et al. 2009). 
Subcellular localization is essential to protein function.  Using distinct 
compartments provides a way to achieve functional diversity and save on protein design 
and synthesis (Butler and Overall, 2009).  Aggregation of amyloidogenic proteins can 
result in the sequestration, inactivation, and irregular localization of numerous proteins.  
Aberrantly localized proteins have been linked to human diseases as diverse as 
amyotrophic lateral sclerosis, cancer, and Swyer syndrome (Winton et al., 2008; Dansen 
and Burgering, 2008; McLane and Corbett, 2009).  In patients with ALS, affected 
neurons exhibit a prominent redistribution and nuclear inclusions of TAR DNA-binding 
protein (TARDBP, also known as TDP43) or the protein fused in sarcoma (FUS) from 




1.1.1 Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is a late-onset neurodegenerative disease.  
Characterization of the disease includes loss of motor neurons, progressive weakness, and 
eventual paralysis leading to death by respiratory failure or pneumonia (Kierman et al., 
2011).  ALS disease progression results in death within 3-5 years of diagnosis (Boillée et 
al., 2006).  Most ALS cases are sporadic, but 10% are familial. Approxamately 20% of 
familial cases result from mutations in the SOD1 gene (encoding Cu/Zn superoxide 
dismutase) and 34% from hexanucleotide repeat expansions in the chromosome 9 open 
reading frame 72 gene (C9ORF72) repeats (Rosen et al., 1993; Blitterswijk et al., 2012).  
SOD1 mutations are thought to cause disease by a toxic gain of function (Bruijn et al., 
1998), thus strategies to lower SOD1 levels are being pursued (Smith et al., 2006). 
However, SOD1 mutations and C9ORF72 repeats account for only a small percentage of 
ALS cases, and additional therapeutic strategies are needed.  RNA-binding proteins and 
RNA-processing pathways have recently been implicated in ALS and may provide 
another possible therapeutic target (Lagier-Tourenne et al., 2010; Gitler et al. 2011). 
1.1.2 TDP-43 aggregation in ALS 
TDP-43 was identified as a major component of the ubiquitinated neuronal 
cytoplasmic inclusions deposited in cortical neurons in FTD and in spinal motor neurons 
in ALS (Neumann et al, 2006). TDP-43-positive inclusions have subsequently been 
shown to be common in 97 % of ALS cases (Mackenzie, et al. 2007, Maekawa et al., 
2009), whether sporadic or familial.  Additionally, mutations in the gene TARDBP, 
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which encodes TDP-43, have been identified in familial ALS and sporadic ALS cases 
(Pesiridis et al., 2009; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 
2008; Yokoseki et al., 2008). Therefore, therapies targeting TDP-43 could be effective in 
cases not caused by SOD1 mutation. Notably, TDP-43 inclusions occur in many 
frontotemporal dementia cases.  Targeting TDP-43 might be an effective therapeutic 
strategy for these patients. Efforts are under way to define the mechanisms by which 
TDP-43 and defects in RNA processing pathways contribute to ALS. 
The exact cellular function of TDP-43 is officially unknown though experiments 
show the protein plays a very important role in several biological systems.  These 
systems either regard the control of gene transcription, selected splicing processes, and in 
the maintenance of mRNA stability. 
Gene expression of HIV-1 is regulated by many host cellular factors.  TDP-43 
was found to inhibit the assembly of transcriptional factors in the regulatory system (Ou 
et al., 1995).  The binding site of TDP-43 was determined using band shift analysis.  This 
sequence was found to be the HIV-1 long terminal repeat known as TAR.  The binding 
section extends from nucleotide -18 to +80 and is important for the activation of gene 
expression.   
The mechanism of TDP-43 toxicity in ALS isn’t fully understood.  Numerous 
models exist.  One model suggests TDP-43 undergoes nuclear export during times of 
cellular stress.  TDP-43 then moves to a stress granule or undergoes liquid-liquid phase 
separation.  Glycine rich C-terminal domain drives aggregation of TDP-43 causing 
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sequestering of vital RNAs and other RNA binding proteins (Figure 1). Various studies 
have examined the roles of TDP-43’s gain or loss of function in disease. Overexpression 
of wild-type TDP-43 recapitulates TDP-43 proteinopathy and disease phenotypes in an 
array of animal models (Johnson et al., 2008; Wils et al., 2010; Li et al., 2010; Ash et al., 
2010).  These results support a role for gain of toxic function in disease. Initial studies 
testing a loss-of-function hypothesis used knock-out of TDP-43 from mice.  The 
complete knock-out of TDP-43 resulted in embryonic lethality (Wu et al., 2010; Sephton 
et al., 2010; Kraemer et al., 2010). These early studies demonstrated TDP-43 plays a vital 
role in early development without necessarily demonstrating that loss of function could 
be degenerative in adulthood. To address these questions, conditional and partial 
knockout models demonstrated loss of TDP-43 function can induce motor neuron defects, 
a progressive motor phenotype reminiscent of human disease, and even typical TDP-43 
proteinopathy (Wu et al., 2012; Iguchi et al., 2013; Kabashi et al., 2010). Interestingly, 
either overexpression or knockdown of TDP-43 selectively in glia or muscle also 
recapitulates ALS-like phenotypes (Yang et al., 2014; Diaper et al., 2013). The emerging 
picture is that both gain and loss of TDP-43 function may be mechanistic in disease and 





Figure 1: Proposed model of aggregation in yeast.  Cellular stress causes nuclear 
export of TDP-43.  TDP-43 moves into stress granule. Glycine rich C-terminal domain 




Human TDP-43 was first isolated in 1995.  The discovery was made while 
searching for novel transcriptional inactivators that bind the TAR DNA element of the 
human immunodeficiency virus type 1 (HIV-1) virus.  TDP-43 is a ubiquitously 












contains two RNA recognition motifs (RRMs) and a glycine-rich C-terminal domain. 
TDP-43’s function is uncertain, but it likely plays important roles in pre-mRNA splicing 
and transcriptional repression (Ayala et al., 2008; Buratti et al., 2001).  The gene coding 
for this protein (TARDBP) is present on Chromosome 1 and consists of 6 exons.  Some 
of these exons may be alternatively spliced to yield various isoforms of the protein 
(Wang et al., 2004). TARDBP is a highly conserved gene throughout evolution and 
relating homologues of human TDP-43 have been found in all higher eukaryotic species.  
Homologues of TDP-43 were found in distant organisms such as Drosophila 
melanogaster, Xenopus laevis, and Caenorhabditis elegans (Wang et al., 2004; Ayala et 
al., 2005).  Such a high degree of sequence conservation hints towards a fundamental role 
played by this protein.   
In ALS and frontotemporal lobar degeneration with ubiquitin-positive inclusions 
(FTLD-U), TDP-43 is depleted from the nucleus and accumulates in ubiquitinated 
cytoplasmic inclusions (Neumann et al., 2006).  Notably, mutations in the TDP-43 gene 
(TARDBP) are linked to sporadic and non-SOD1 familial ALS.  This implies that TDP-
43 abnormalities are likely one cause of the disease (Kabashi et al., 2008; Sreedharan et 
al., 2008; Van Deerlin et al., 2008; Rutherford et al., 2008; Gitcho et al., 2008; Yokoseki 
et al., 2008).   
1.2.1 TDP-43 Structure 
Full open reading frame of TARDBP consists of 1,245 base pairs coding for 414 
amino acids.  The theoretical molecular weight of TDP-43 is 44,740 Daltons.  TDP-43 
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contains two highly conserved RNA Recognition Motifs (RRM1 and RRM2) flanked by 
an N-terminal and a C-terminal tail (Figure 2).  This primary amino acid structure 
resembles that of members of the heterogeneous ribonucleoprotein (hnRNP) family 
(Krecic et al., 1999; Dreyfuss et al., 2002).  The c-terminal tail contains a glycine-rich 
region often found in proteins to mediate protein-protein interactions.   
TDP-43 was found to natively dimerize in normal cells under physiological 
conditions (Shilina et al., 2010).  Formation of a monomer results in a more aggregation 
prone protein.  	
Figure 2: Domain structure of TDP-43.  Protein contains a N-terminal domain, 
two RNA binding motifs, and a “prion-like” unstructured C-terminal domain. 
1.2.2 TDP-43 Functions 
Eukaryotic gene expression requires the coupling of many processes.  These 
processes include transcription, pre-mRNA processing, mRNA transport, and translation 
(Maniatis et al, 2002; Proudfoot et al., 2002).  Proteins that take part in these processes 
are not confined to singular roles.  The functions performed by TDP-43 seem to be 
decided by the sequence specificity of the RRM domains.  Previous research 
demonstrated TDP-43 binds single stranded TG and UG repeats with high affinity via the 
RRM1 domains (Ayala et al., 2005; Buratti et al., 2001).  At least 5 repeated units (UG5) 
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are necessary for efficient binding of TDP-43 and efficiency increases with increased 
length (Ayala et al., 2005).  
Much less is known about the function of the N-terminal domain.  The N-terminal 
domain is loosely conserved compared to the RRM domains.  The length of the N-
terminal region varies in different species.  The average of most species is 105 residues 
compared to 174 residues in C. elegans.  Contrary to the lack of conservation in length, a 
striking example of conserved sequence exists in a 15-nucleotide region highly enriched 
in acidic amino acids near the N-terminus of TDP-43 (Buratti et al., 2001).  
1.2.3 TDP-43 is Intrinsically Aggregation Prone 
In the absence of other components, TDP-43 spontaneously forms aggregates 
bearing ultrastructural similarities to TDP-43 deposits in degenerating neurons of ALS 
FTLD-U patients (Johnson et al., 2009).  The C-terminal of TDP-43 was also found to be 
important for aggregation.  Truncation of the C-terminal led to a loss of toxicity and 
aggregation (Johnson et al., 2009).  Of the over 25 recently reported ALS- linked TDP-43 
mutations, all but one mutation can be found within this domain (Banks et al., 2008). 
Furthermore, similar aggregated C-terminal fragments accumulate in ALS and FTLD-U 
(Neumann et al., 2006).  
1.2.4 TDP-43 Liquid-Liquid Phase Separation 
 Stress granules are membrane-less assemblies generated by the condensation of 
protein and nucleic acid components into liquid phases that self-segregate in the cell.  
Like other ALS-associated RNA-binding proteins, TDP-43 has been shown to undergo 
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liquid-liquid phase separation (LLPS) (Molliex et al., 2015).  The N and C-termini of 
TDP-43 can drive the phase separation (Schmidt et al., 2016).  Three tryptophan residues 
(Trp-334, Trp-385, and Trp-412) are the most important residues for TDP-43 LLPS. 
These results also suggest that only a few residues might be required for TDP-43 LLPS 
due the self-assembling tendency of the α-helical segment in the middle part of the C-
terminal.  This reduces the number of motifs required for formation of multiple binding 
sites (Li et al., 2018).  Furthermore, there’s evidence that disruption of LLPS increases 
the pathological fibrilization of these ALS-associated RNA-binding proteins (Taylor et 
al., 2017).   
1.2.5 Mutations of TDP-43 
Numerous mutations of TDP-43 have been found in patients with ALS.  Testing 
of these mutations in vivo and in vitro has yielded various results.  ALS-associated TDP-
43 inclusions are primarily fragments.  These fragments often include the entire CTD 
(Neumann et al., 2006). The CTD is classified as “prion-like” due to a resemblance to the 
amino acid frequency in yeast prion domains.  This includes a low complexity 
composition rich in polar while also and poor in aliphatic and charged residues (King et 
al., 2012). The domain proves to be aggregation-prone in both in vitro and in vivo models 
of ALS (Budini et al., 2015; Johnson et al., 2009; Wegorzewska et al., 2009). 
Additionally, mutations in the CTD can have a profound effect on the behavior of the 
domain.  TDP-43 C-terminal domain liquid-liquid phase separation is mediated by 
intermolecular interactions that include contacts involving the 321-340 region. ALS 
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mutations (A321G, Q331K, and M337V) significantly disrupt phase separation 
stimulating the conversion to aggregates.  Some of these mutations result in a disruption 
of the helical structure (possibly leading to an increase in aggregation) (Conicella et al., 
2016). 
Native dimerization of TDP-43 occurs via the N-terminal domain interface.  This 
interface mainly occurs by way of hydrogen bonding and electrostatic forces between the 
N-terminal domain and RRM domains of two TDP-43s.  Mutation of serine to glutamic 
acid at the 48th residue disrupts hydrogen bonding in the interface and weakens the 
assembly of the dimeric state by removing the hydrogen bonding and electrostatic 
interaction capabilities (Wang et al., 2018).  
Mutations in the RRM1 have also been assessed.  Mutating phenylalanine 147 
and phyenylalanine 149 to leucines result in the inability of TDP-43 to bind RNA or 
DNA (Buratti et al., 2001).  TDP-43 can no longer bind DNA or RNA due to the loss of 
pi-pi stacking interactions in the domain. 
1.2.6 Enhancing TDP-43 Solubility Via RNA Binding 
TDP-43 is a 414-amino acid nuclear protein composed of two highly conserved 
RNA recognition motifs (RRM1 and RRM2) and a glycine rich C-terminal region. Both 
RRMs are involved in binding of RNA/ DNA sequences enriched in UG or TG repeats.  
Recent findings also suggest that RNA/DNA binding modulates TDP-43 solubility 
(Pesiridis et al., 2011; Huang et al., 2013).  These studies have shown that poly-TG 
compounds can increase the solubility of refolded recombinant TDP-43 under 
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aggregation conditions induced by temperature (Huang et al., 2013).  These experiments 
provided evidence that inhibition of aggregation occurs by preservation of the protein’s 
native dimeric state and prevention of a monomeric state.  Additionally, poly-TG 
compounds increase the solubility of TDP-43 greater than naturally occurring nucleotide 
targets (Sun et al., 2014).    Length of TG/UG repeats and molar concentration of the 
repeats also had an inverse relationship with Kd values (Bhardwai et al., 2013).  These 
discoveries provide a possible method of preventing TDP-43 aggregation using DNA or 
RNA therapies.  Increaseing the stability of RNAs in the cytoplasm may also play a role 
in therapy effectiveness. 
1.3 mRNA Structural Stability 
Recent studies have revealed that long non-coding RNA (lncRNA) stability varies 
widely (<0.5 h to >48 h).  These findings hint at transcript half-life being one factor that 
regulates biological function (Clark et al., 2012; Tani et al., 2012). Messenger RNA 
(mRNA) degradation rates change in response to stimulus.  This allows cells to quickly 
increase or decrease mRNA abundance to meet a cell’s needs for specific proteins.  
Collections of bound proteins and noncoding RNAs dictate mRNA degradation rates 
through their ability to recruit (or exclude) the mRNA degradation machinery.  
Deadenylation dependent mRNA decay is the major pathway in mammalian cells. One or 
a combination of three deadenylases performs poly(A) tail removal. These particular 




Following deadenylation, degradation of a mRNA continues in a 5′ to 3′ or 3′ to 5′ 
direction.  3′ to 5′ decay of the mRNA body requires the 10 to 12 subunit exosome.  This 
contains RNase PH-domain enzymes, S1 and KH-family RNA-binding proteins, RNase 
D-like enzymes, and RNA helicases (Mukherjee et al., 2002; Houseley et al., 2006). 
When only a few 5′ nucleotides of the mRNA remain, the decapping enzyme DcpS 
removes the 5’ cap structure (Liu et al., 2002). 5′ to 3′ mRNA decay begins with 
decapping.  Dcp1 and Dcp2 proteins come together to perform the decapping. Decapping 
requires several other proteins including Lsm1–7 (bound at the 3′- end of the 
deadenylated product), hEdc3, Rck/p54, and Hedls. Hedls enhances the decapping 
activity of Dcp2 and promotes complex formation between Dcp1-Dcp2 (FengerGron et 
al., 2005). Xrn1 degrades the mRNA following decapping. 
Figure 3: Representations of 5’ and 3’ mRNA decay.  Deadenylation One or a 
combination of three deadenylases performs poly(A) tail removal.  Following 
deadenylation, degradation of a mRNA continues in a 5′ to 3′ or 3′ to 5′ direction.  5’ to 
3’ decay proceeds with 5’ decapping by DCP1 and DCP2  followed by decay via XRN1.  
3’ to 5’ decay proceeds with decay using a 3’ exosome until only a few nucleotides 
remain.  5’ decapping then occurs via DcpS. 
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1.3.1 XRN1-resistant RNA (xrRNA) 
Flaviviruses are single-stranded positive-sense RNA viruses (Bhatt et al., 2013; 
Mackenzie et al., 2004; Normile et al., 2013). The flavivirus genus includes, but is not 
limited to, West Nile Virus, dengue virus, yellow fever virus, and Zika virus (Chambers 
et al., 1990).  Most of these viruses are transmitted by bite from an infected mosquito or 
tick.  During infection, not only is the viral genomic RNA (gRNA) replicated, but 
specific 300–500 nucleotide-long subgenomic flaviviral RNAs (sfRNAs) also accumulate 
from the incomplete degradation of the 3’ untranslated region (3’UTR) (Pijlman et al., 
2008).  This incomplete degradation is performed by the 5’to 3’ host-cell exonuclease 
Xrn1 (Jones et al., 2012).  sfRNAs form from a halt in degradation at defined locations 
within the gRNA’s 3’UTR (Pijlman et al., 2008).   
Sequence alignment of xrRNA suggests a shared structure.  Helices P1 and P2 of 
the RNA stack coaxially while helix P3 is at an acute angle relative to P1 (Chapman et 
al., 2014).  This structure is consistent with other RNA three-way junctions from 
flaviviruses (Lescoute et al., 2006). Together, helices P1 and P3 form a ring-like 
structure. The continuous loop comprised of Nucleotides 33-49 resides entirely on one 
side of the structure. The 5’end of the xrRNA passes through the center of the ring.  Xrn1 
encounters the compact and concave ring-like side of the xrRNA as it degrades the RNA 
in a 5’ to 3’ direction (Chapman et al., 2014).   
Upon encountering the concave ring-like structure, Xrn1 must pull the 5’ end of 
the RNA through the ring. Unfolding this xrRNA requires Xrn1 to essentially turn the 
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structure inside out. During strand synthesis, the virally encoded RNA polymerase would 
not encounter this impediment as it approachs from the 3’ end.  This suggests the 
characteristic of unidirectional resistance (Chapman et al., 2014). 
1.3.2 3’ Expression and Nuclear Retention Element (ENE) 
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly 
abundant, nuclear-localized lncRNA. MALAT1 is also a precurser for the tRNA-like 
structures known as mascRNA.  The structures are substrates for RNase P (Hutchinson et 
al., 2007; Bernard et al., 2010; Stadler, 2010; Wilusz et al., 2008; Sunwoo et al., 2009). 
The resulting 5′-cleavage products of MALAT1 end with a highly conserved sequence.  
This sequence contains two U-rich motifs and a genomically encoded A-rich tract at the 
3′ end (Wilusz et al., 2008; Sunwoo et al., 2009). In vitro decay assays have shown a 
destabilization effect from mutations in the U-rich motifs and A-rich tract in mouse 
MALAT1 RNA fragment.  This result suggests the structure of this region contributes to 
RNA stability despite the lack of a traditional poly(A) tail (Wilusz et al., 2008; 
Guhaniyogi et al., 2001).  This structure has U•A-U base triples flanked by two stems. 
The 3′ sides of the U-rich internal loops can form 11 consecutive Watson–Crick base 
pairs with the downstream A-rich tract, and the 5′ sides are proposed to engage in 
Hoogsteen interactions.  Analyses of the MALAT1 ENE revealed that stabilization 
activity requires an intact triple helix, strong stems at the duplex-triplex junctions, a G-C 
base pair flanking the triplex to mediate potential A-minor interactions, and the 3′-
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terminal A of the A-rich tract to form a blunt-ended triplex lacking unpaired nucleotides 
at the duplex- triplex junction (Brown et al., 2012) 
1.4 Saccharomyces cerevisiae Genomics 
The budding yeast, Saccharomyces cerevisiae (S. cerevisiae), serves as an 
important experimental organism for revealing gene function. In addition to carrying out 
all the basic functions of eukaryotic cells, up to 30% of positionally-cloned genes 
implicated in human disease have yeast homologs (Bassett et al., 1997).  S. Cerevisiae are 
also utilized because of the ease with which it can be manipulated.  For these reasons, S. 
cerevisiae research serves as a model organism for a variety of processes that occur in 
humans. 
The Gateway® cloning method for use in S. cerevisiae was developed to address 
the time-consuming nature of standard cloning methods.  The system adapted the pRS 
series of yeast shuttle vectors. These vectors are based on the site-specific recombination 
properties of the bacteriophage lambda (Landy, 1989).  The lambda recombination 
system requires two major components: DNA recombination sites and enzymes to 
facilitate the recombination reaction.  A mixture of enzymes that bind to specific 
sequences catalyzes the recombination.  The enzymes bring together the target sites, 
cleave them, and covalently attach the DNA. Recombination occurs following two pairs 
of strand exchanges and ligation of the DNAs in a novel form. The recombination 
proteins involved in the reaction differ depending upon whether lambda utilizes the lytic 
or lysogenic pathway.  The lysogenic pathway is catalyzed by the bacteriophage λ 
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Integrase (Int) and E. coli Integration Host Factor (IHF) proteins (BP ClonaseTM enzyme 
mix).  The bacteriophage λ Int and Excisionase (Xis) proteins, and the E. coli Integration 
Host Factor (IHF) protein catalyze the lytic pathway (LR Closest enzyme mix) (Landy, 
1989; Ptashne, 1992). 
Figure 4:  Gateway Clonase reactions:  BP reactions follow the Lysogenic pathway.  
LR reactions follow the Lyctic pathway.  Each pathway uses a unique set of enzymes to 
accomplish the recombination reaction. 
ORFs are first moved from a PCR product or entry clone to a donor vector.  At this 
stage, ORFs are flanked by attB sites.  The attB sites on the ORF react with the attP sites 
on a donor vector.  This BP reaction results in the ORF in a donor vector with attL sites.  
The new donor vector is then moved from the donor vector to a destination vector.  This 
stage utilizes the attL sites on the donor vector and attR sites on the destination vector.  
This LR reaction results in the ORF in a destination vector with attB sites. 
288 yeast Gateway® vectors were developed using two commonly used GPD and 
GAL1 promoter expression systems. Using these systems enable expression of ORFs 
either constitutively or under galactose-inducible conditions. The expression system also 
enables proteins of interest to be fused to a choice of frequently used N- or C-terminal 
tags.  These tags include EGFP, ECFP, EYFP, Cerulean, monomeric DsRed, HA or TAP. 
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Figure 5: Gateway Destination Vector.  2µ ori: fragment from the 2 micron circle (a 
natural yeast plasmid) allows for 50+ copies to stably propogate per cell..  AmpR: coding 
sequence gives E coli containing the plasmid ampicillan resistance.  attR1 and attR2 sites 
for site specific recombination.  ccdB gene: bacterial toxin that poisons DNA gyrase for 





1.4.1 Using Yeast as a TDP-43 Proteinopathy Model 
TDP-43 toxicity and aggregation were reported using yeast (Johnson et al., 2008).  
This model recapitulates numerous distinctive cellular features of human TDP-43 
pathology, including conversion from nuclear localization to cytoplasmic aggregation.  
The pathological features of TDP-43 are distinct from those of other protein-misfolding 
diseases in yeast models (Johnson et al., 2008). This suggests that rather than general 
cellular stresses associated with accumulating misfolded proteins, the yeast model reveals 
specific aspects of the underlying biology of the disease associated with TDP-43 
aggregation. This work provided framework for investigating the toxicity of TDP-43 
aggregation relevant to human disease while also establishing a manipulable model for 
discovering potential therapeutic strategies (Johnson et al., 2008). 
The manipulability of yeast provided the ability to perform a genome-wide screen 
to identify genes that modify TDP-43 toxicity (Giaever et al., 2002).  Deletion of the 
lariot debranching enzyme (dbr1) provided the most potent suppressor of TDP-43 
toxicity (Armakola et al., 2012). dbr1 catalyzes the debranching of lariat introns that are 
formed during pre-mRNA splicing.  In yeast, it was shown that inhibiting the 
debranching enzymatic activity of dbr1 sufficiently rescued TDP-43 toxicity (Armakola 
et al., 2012).  Evidence was also provided that intronic lariat species that accumulate in 
the cytoplasm of dbr1∆ cells act as decoys to sequester toxic cytoplasmic TDP-43 
(Armakola et al., 2012).  This possibly prevents aggregated TDP-43 from interfering with 
other essential cellular RNA targets and RNA-binding proteins. Knockdown of dbr1 in a 
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human neuronal cell line and in primary rat neurons is also sufficient to rescue TDP-43 
toxicity, suggesting that the effect of dbr1 on TDP-43 toxicity is conserved from yeast to 
mammals (Armakola et al., 2012). 
1.5 RNA Aptamers 
Nucleic acids were once only considered as the key molecules solely involved in 
storage and expression of genetic information.   That narrow outlook changed after the 
discovery of non-coding RNAs. These RNAs exploit the structural characteristics of 
nucleic acids to execute a variety of functions.  These functions include gene regulation, 
catalysis, and specific ligand binding (McKeague et al., 2012). Following this discovery, 
a new class of synthetic nucleic acid molecules called “Aptamers” developed. These are 
small single stranded DNAs or RNAs.  These DNAs and RNAs range from 15 to 150 
nucleotides with an ideal length of 20-40 nucleotides (Wang et al., 2012).  These DNAs 
and RNAs fold into a well-defined three–dimensional structure.  These structures allow 
binding to target ligands with high affinity and specificity (Mayer, 2009; Tuerk et al., 
1990).    
1.5.1 MS2 System 
Aptamers have been developed to visualize RNA in vivo.  In 1998, a method was 
introduced to visualize mRNA dynamics in live cells using an MS2-GFP coat protein.  
The system utilizes bacteriophage MS2 operator hairpin and coat protein.  The coat 




In this system, the sequence of aptamers (MS2 Hairpins) that recognize the MS2 
coat protein is added to the untranslated region of the target RNA. The cells are 
transfected with this construct and the expression construct for the MS2 coat protein 
fused to GFP. Expression of the tagged RNA can now be visualized via the bound MS2-
GFP protein. Applying this technique has enabled several insights into the process of 
mRNA trafficking. 
1.5.2 Spinach Aptamer 
Protein based imaging systems are useful for tracking and imaging RNA, but their 
applications are limited by high background from the unbound protein. To avoid these 
limitations, fluorophore molecules have been developed and aptamers were designed 
against these fluorophores. Specification of these small molecules require them to be 
non-toxic, easily permeable, and provide low non-specific binding to cellular 
components. Fluorophores have been designed to provide all the above criteria and 
provide a low fluorescence in the free state and provide fluorescence increases upon 
binding to their specific aptamer. Malachite green is one such fluorophore. The 
intramolecular motions are restricted upon aptamer binding.  This binding and 
conformation restriction leads to ~2360 times increase in fluorescence (Babendure et al., 
2003). When the Hoechst 1c (Sando et al., 2008) small molecule binds with nanomolar 
affinity, their fluorescence increases 50-60 fold. Recently, a GFP fluorophore analog, 3,5-
difluoro-4- hydroxybenzylidene imidazolinone (DFHBI), was discovered.  This small 
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molecule becomes fluorescent when it binds to an RNA aptamer known as Spinach 
(Paige et al., 2011). 
The spinach aptamer has been utilized to image highly abundant RNA like the 5S 
rRNA in bacterial and mammalian cells and has been applied as a sensor to image 
intracellular metabolites (Paige et al., 2012).  DFHBI also provided a means to visualize 
the ASH1 gene is S. cerevisiae validating this technology in yeast (Guet et al., 2015).  
Binding of DFHBI to the RNA promotes stabilization of the transducer stem enabling the 
Spinach RNA to fold and bind DFHBI.  Binding of DFHBI to the spinach RNA then 
causes fluoresces of the small molecule, limiting the background. 
1.6 Research Aim 
TDP-43 was recently found as the major protein in ubiquitinated inclusions in 
ALS (Neumann et al., 2006).  When TDP-43 toxicity is tested in dbr1 deleted yeast, the 
build-up of lariats proves to rescue tdp-43 toxicity by acting as a decoy.  Taking the 
knowledge of bound RNA to TDP-43 stabilized dimerization, TDP-43 toxicity could be 
rescued by synthetic RNAs.  The main aims of this thesis are: 
• To demonstrate different aggregation properties of wild type TDP-43 and mutant 
TDP-43. 
• To demonstrate a difference in wild type TDP-43 and mutant TDP-43 toxicity in 
S. cerevisiae. 
• To present evidence from yeast spotting assays and confocal microscopy showing 
how in vitro synthesized RNAs affect TDP-43 toxicity in yeast. 
22 
 
Chapter Two: Materials And Methods 
2.1 Yeast Strains, Media, and Plasmids 
Yeast were obtained from GE Dharmacon.  Yeast parental strain BY4730 (catalog 
# YSC1061) were used for experiments.  Yeast cells were grown in rich yeast peptone 
dextrose media (YPD) or in synthetic media lacking leucine and containing 2% glucose 
(SD/-Leu), raffinose (SRaf/-Leu), or galactose (SGal/-Leu). 1 liter of YPD was prepared 
by adding 20 g yeast extract and 10 g peptone to 900 mL H2O.  The solution is then 
autoclaved for 30 minutes.  100 mL 20% dextrose is then added to the solution before 
use.  
Yeast containing a deletion of the lariat debranching enzyme dbr1 were obtained 
from Dharmacon, Inc. (catalog number YSC6273-201926517).  Deletion of dbr1 was 
further selected for on plates containing YPD+G418 (200 µg/mL).  When plasmids 
containing auxotrophic markers were transformed into dbr1Δ cells, cells were selected 
for on plates containing                           
A Yeast Gateway Kit (Kit # 1000000011) was obtained from Addgene.  The kit 
containing 285 yeast Gateway destination vectors based on a widely used pRS series of 
yeast shuttle vectors and contained two commonly used GPD and GAL1 promoter 
expression systems.  
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To generate C-terminally DsRed-tagged or GFP-tagged TDP-43 constructs, a 
PCR protocol was used to amplify TDP-43 without a stop codon and incorporate the 
Gateway attB1 and attB2 sites.  AttB1 and a primer consisting attB2 plus the 3’ end of 
TDP-43 (omitting the stop codon).  Q5® High-Fidelity DNA Polymerase was used to 
perform the site directed mutagenesis.  The resulting PCR products were purified using 
the Zymo Research DNA Clean & Concentrator. 
AttB1  5’GGGGACAAGTTTGTACAAAAAAGCAGGCT3’ 
attB2+3’TDP43 5’ACCACTTTGTACAAGAAAGCTGGGTTCATTCCCCAGCCAGAAGAC3’  
To generate a C-terminally DsRed-tagged or GFP-tagged TDP-43 mutant 
constructs (Figure 9), a PCR protocol was used to amplify the previously described TDP-
43 with the desired mutation.  One TDP-43 mutant was generated by deleting amino 
acids 307-414.  This C-terminal domain deleted (ΔCTD) mutant proved does not 
aggregate but still contains RRM1 and RRM2 for binding of RNA/DNA (Johnson et 
al.,2007). Johnson also found the mutant to be non-toxic in yeast.  AttB1 and a primer 
consisting attB2 plus the coding sequence for amino acids 408-414.  Q5® High-Fidelity 
DNA Polymerase was used to perform the site directed mutagenesis.  The resulting PCR 
products were purified using the Zymo Research DNA Clean & Concentrator. 
attB1  5’GGGGACAAGTTTGTACAAAAAAGCAGGCT3’ 
attB2+3’TDP43 5’ACCACTTTGTACAAGAAAGCTGGGTATTACTACCTTGATTGTT3’ 
To generate a negative control containing a C-terminal fluorescent protein, a PCR 
protocol was used to generate the coding sequence for the first 6 amino acids from yeast 
GAPDH.  One primer containing the sequence for attB1 and the first 15 amino acids of 
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GAPDH.  The other primer contained the sequence of attB2 and the first 17 amino acids 
of GAPDH.  The first 15 nucleic acids of primer 1 are the reverse compliment of last 15 
nucleic acids of primer 2.  PCR was used to anneal the primers.   
attB1+5’GAPDH 5’GGGGCAAGTTTGTACAAAAAAGCAGGCTATGATCAGAATTGCT3’ 
attB2+3’GAPDH 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTAATAGCAATTCTGATCAT3’ 
The 76 base-pair PCR product (GAPDH segment) was purified by a phenol-
chloroform extraction followed by an ethanol precipitation.  An equal volume of 
25:24:1(v/v/v) phenol/chloroform/isoamyl alcohol was added to the PCR product.  The 
mixture was mixed using a vortex for 30 seconds before being centrifuged for 30 
seconds.  The aqueous phase was carefully removed by pipette and transferred to a new 
tube.  3M Sodium acetate was added to the PCR product (final concentration of 0.3M 
sodium acetate).  2.5 volumes of ice-cold 100% ethanol was then added to the mixture.  
The solution was then placed at -80oC for at least 15 minutes.  The solution was then 
centrifuged in a fixed angle microcentrifuge at 21,330 RCF for 5 minutes.  The 
supernatant was then removed before1 mL of 70% ethanol was added to the pellet.  The 
tube was mixed by inversion before being centrifuged at 21,330 RCF for 5 minutes in a 
fixed angle microcentrifuge.  The pellet was dried before being resuspended in molecular 
biology grade H2O. 
Resulting PCR products were shuttled into pDONR221 using a Gateway BP 
reaction. The BP reaction resulted in pDONR221 containing TDP-43 flanked with attL1 
and attL2.  Each BP reaction contained: 150 ng PCR product, 150 ng Pdonr221, TE 
buffer (to 4 µL), and 1 µL BP Clonase II Mix (ThermoFisher catalog # 11789020). 
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A Gateway LR reaction was the used to shuttle TDP-43 into the Gateway-
compatible yeast expression vectors pAG425GAL-ccdB-DsRed (Figure 8) and 
pAG425GAL-ccdB-eGFP. The fused DsRed fluorescent protein acts a true monomer.  
This generation of DsRed accomplishes proper localization and a quicker maturation 
half-life of 40 minutes—improvements on previous tetrameric DsRed proteins which 
colocalized and had a maturation half-life of 12 hours (Strongin et al., 2007).  Each LR 
reaction contained: 150 ng PCR product, 150 ng destination vector, TE buffer (to 4 µL), 
and 1 µL LR Clonase II Mix (ThermoFisher catalog #11791100). 
To generate constitutively active RNA decoys (Figure 7A), custom DNA flanked 
by the Gateway attB1 and attB2 was obtained from Integrated DNA Technologies.  The 
open reading frame consisted of two Dengue Virus xrRNA structures, RNA binding 
domain (Figure 6), spinach aptamer, MS2 hairpins, 3’ ENE, and Civ1.2Rz ribozyme.  
The designed DNA sequences were shuttled into pDONR221 using a Gateway BP  
reaction. The BP reaction resulted in pDONR221 containing the custom DNA flanked 
with attL1 and attL2.  A Gateway LR reaction was the used to shuttle custom DNA into 
the Gateway-compatible yeast expression vectors pAG423GPD-ccdB (Figure 8). 
Figure 6: Sequences for binding domains used for RNA decoys.  UG rich sequences 
shown in bold. 
RNA decoys were also tested in plasmids previously used to test xrRNA stability 
(Figure 7B).  Two BglII sites were used to remove the previous insert by a single 





xrRNAs, 12 TG repeat binding domains (Figure 6), a spinach RNA aptamer, and a 
Cricket paralysis virus IRES. One insert contained two consecutive xrRNAs, a spinach 
RNA aptamer, and a Cricket paralysis virus IRES. The last insert contained two 
consecutive mutated xrRNAs (First three nucleotides in the pseudoknot GTCàCAG), 12 
TG repeat binding domains, a spinach RNA aptamer, and a Cricket paralysis virus IRES.  
All 3 inserts are flanked by BglII digest sites to allow ligation with the backbone. 
 
Figure 7: RNA decoy designs used in yeast.  A.  Decoy used in the Gateway system.   
B.  Decoy used in the JPS-1481 system.  Both designs contain a decay resistant structure, 
TDP-43 binding site, and aptamer for RNA labeling. 
Transformations were performed to obtain yeast containing the generated 
constructs.  Plasmid DNA was transformed using the PEG/lithium acetate method.  Yeast 
were grown to mid-log phase.  Yeast were then washed with qH2O before being 
resuspended in 100 mM lithium acetate.     Finally, yeast cells were resuspended in 50 µL 
per transformation qH2O.  For each transformation, 50 µL cells were combined with 
10µL ssDNA, 1µg DNA, and 500 µL PLATE (40% PEG 3350, 100mM LiOAc, 10 mM 







Figure 8: Overview of cloning used to obtain expression vectors.  PCR product 
flanked by attB sites reacts with entry vector with attP sites in a lysogenic (BP) reaction.  
Resulting product (with attL sites) then reacts with destination vector (attR sites) in a 
lyctic reaction to produce the expression vector with attB sites. 
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block.  Cells were then plated on a selection media plate depending on the auxotrophic 
marker.  Plates were placed in an incubator for at least 24 hours at 30oC.  Culture was 
then taken and struck on a selection media plate for single colonies. 
		
 
Figure 9: Location of each mutation made and tested.  1. Lysine to glutamine 
substitution at residue 331  2. Serine to glutamic acid at the 48th residue.  3. Two separate 
phenylalanine to leucine substitutions. 4.  C-terminal truncation at amino acid 306. 
2.2 Yeast Spotting Assays 
To measure cell viability, yeast-spotting assays were performed. Yeast cells were 
grown overnight at 30°C in synthetic liquid media lacking leucine and containing glucose 
(Glu/-Leu).  5 mL of fresh SD media were then seeded from the overnight culture (100 
µL of overnight culture into 5 mL fresh media) and grown at 30°C until they reached log 
or mid-log phase.  Culture ODs were then normalized, serially diluted in a 96 well plate, 
and spotted onto synthetic solid media containing glucose or galactose lacking leucine 
using a V&P Scientific 48 pin Multi-Blot Replicator (cat# VP407AH).  The plates were 




4.  C-terminal 
truncation 
(at amino 
acid 306)  
2.  S48E 3.  Two separate 
phenylalanine to 
Leucine substitutions  
1.  Q331k 
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2.3 Confocal Microscopy 
To visualize TDP-43 aggregates, yeast cells were grown overnight at 30°C in 
synthetic liquid media lacking leucine and containing raffinose (SRaf/-Leu) until they 
reached log or mid-log phase.  Cells were then spun down at 3426 rcf, resuspended in 
synthetic media containing glucose or galactose lacking leucine, then incubated at 30°C 
for 4 or 18 hours.  Cells were then fixed using 3.7% formaldehyde for 15 minutes.  After 
fixation, cells were washed twice using phosphate buffered saline.  Cells were then 
permeabilized using 0.1% triton-x for 7 minutes.  After permeabilization, cells were 
washed twice using phosphate buffered saline.  Final resuspension of the cells was done 
in 200 µL PBS.  1 µL of the cell suspension was then combined with 5 µL DAPI 
mounting media.  Cells were cover slipped, sealed with nail polish, and placed in a light 
protective slide holder.  Slides were then imaged on an Olympus FV3000 Confocal Laser 
Scanning Microscope using a 100x objective.  DAPI laser conditions were set at 1% laser 
power, 700V, 1.0X gain, and 3% offset.  Ds-Red laser conditions were set at 0.5% laser 
power, 510 V, 1.0X gain, and 3% offset. 
2.4 Live Cell Imaging 
Live cells were imaged to visualize RNA decoys and perform fluorescence 
recovery after photobleaching (FRAP).  Yeast cells were grown overnight at 30°C in 
synthetic liquid media lacking leucine and containing raffinose (SRaf/-Leu) until they 
reached log or mid-log phase.  20% glucose or galactose was then added to the cultures to 
reach a final concentration of 2%.  Cultures were then placed back at 30°C for 3.5 hours.  
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DAPI was then added at a final concentration of 2.5 µg/mL and cultures were placed 
back at 30°C for 30 minutes.  100 µL cell suspension added to wells coated in 
concanavalin A.  1 µL of 10 mM DFHBI was thenadded to wells. The plate was then left 
at 30oC for 20 minutes before removing the top liquid from wells. Wells were then 
washed with SD media containing 100 µM DFHBI.  100 µL fresh SD media containing 
100 µM DFHBI added to wells before imaging.  Cells imaged on an Olympus FV3000 
Confocal Laser Scanning Microscope using a 100x objective.  Ds-Red laser conditions 




Chapter Three: Results 
3.1 Wild Type TDP-43 Toxicity versus TDP-43 mutants 
To identify toxicity differences between wild type TDP-43 and mutants of TDP-
43, yeast-spotting assays were performed on wild type yeast containing plasmids coding 
for C-terminally DsRed tagged TDP-43 or a mutant TDP-43 on a galactose promoter.  To 
ensure the DsRed fluorescent protein didn’t have a toxic effect on the yeast, the first 6 
amino acids of yeast GAPDH were linked to the DsRed fluorescent protein on the C-
terminal.  Yeast were serially spotted on an auxotrophic selective plate containing 
glucose (expression off) or galactose (expression on). Spotting on a glucose plate ensured 
consistent spotting between all test groups and a baseline for no toxicity.    
Yeast containing expression plasmids coding for DsRed showed viability equal to 
yeast on the glucose plate (expression off).  TDP-43 showed high levels of toxicity 
compared to yeast containing plasmids coding for DsRed.   Yeast expressing Q331K or 
S48E showed equal levels of toxicity compared to yeast containing plasmids coding for 
TDP-43.  RRM mutant showed cell viability equal to yeast containing DsRed 
 plasmids.  ΔCTD showed lower levels of toxicity compared to TDP-43.  Cells still 




Figure 10: Yeast spotting assay comparing wild type TDP-43 to varous mutants of 
TDP-43. Fivefold serial dilution of yeast cells spotted onto glucose (TDP-43 off) or 
galactose (TDP-43 on). 
 
3.2 TDP-43 and TDP-43 mutant Toxicity in Wild-Type and dbr1Δ Yeast 
To identify wild type and mutant TDP-43 toxicity differences in wild type and 
dbr1Δ yeast, yeast-spotting assays were performed with wild type and dbr1Δ yeast 
containing plasmids coding for C-terminally DsRed tagged TDP-43 or a mutant TDP-43 
on a galactose promoter.   Deletion of the dbr1 gene previously showed rescue 
capabilities from TDP-43 toxicity (Johnson et al., 2012).  dbr1Δ expresses the lariat 
debranching enzyme which takes part in intron turnover.  Without the lariat debranching 
enzyme, cells can no longer debranch lariats during pre-mRNA splicing.  Intronic lariat 
species accumulate in the cytoplasm of dbr1∆ cells and act as decoys to sequester toxic 
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cytoplasmic TDP-43, possibly preventing it from interfering with other essential cellular 
RNA targets and RNA-binding proteins.  
Yeast containing expression plasmids coding for DsRed showed viability equal to 
yeast on the glucose plate (expression off) in both wild type and dbr1Δ cells.  As 
previously demonstrated, dbr1Δ cells showed rescue of TDP-43 toxicity compared to 
wild type yeast.  dbr1Δ cells also showed rescue of Q331k toxicity compared to wild type 
yeast.  Cells containing RRM mutant showed cell viability equal to yeast containing 
DsRed plasmids in both wild type and dbr1Δ.		ΔCTD showed lower levels of toxicity 
compared to TDP-43 in both wild type and dbr1Δ	cells.  Complete rescue of ΔCTD 




Figure 11: Yeast spotting assay comparing wild type TDP-43 to varous mutants of 
TDP-43 in wild type and dbr1Δ yeast 
3.3 Wild Type TDP-43 Aggregation versus TDP-43 mutants 
To identify aggregation differences between wild type TDP-43 and mutants of 
TDP-43, wild type yeast containing plasmids coding for C-terminally DsRed tagged 
TDP-43 or a mutant TDP-43 on a galactose promoter were observed using a confocal 
microscope.  To ensure the DsRed fluorescent protein didn’t aggregate, a construct 
containing the first 6 amino acids of GAPDH with a C-terminal DsRed tag was also 
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tested.  Yeast were grown to mid-log phase before being resuspended in SD media 
containing glucose (expression off) or galactose (expression on). Cultures were then 
grown for 4 or 18 hours before being fixed and permeabilized.  1 µL of cell suspension 
was added to 5 µL of DAPI mounting media.  Cover slides were added and sealed with 
nail polish.  Negative control samples (left in glucose) were used to find appropriate 
threshold values when preparing images (Figure 12).  A sum was taken of all z-stacks in 
each image.  A lower contrast level of 500 relative fluorescent units for the DsRed 
channel was found appropriate for negative controls.  This lower threshold was then used 
for all images. 
After 4-hour induction, wild type TDP-43 and Q331K show cytoplasmic 
inclusions when highly expressed in the cell.  Wild type TDP-43 show fewer puncta per 
cell compared to Q331K (Figure 13).  18-hour inductions of Q331K result in fewer, but 
larger, cytoplasmic inclusions.  Wild type TDP-43 inclusions after an 18-hour induction 
are more similar in aggregation tendacies to Q331K after a 4-hour induction (Figure 14). 
Cells containing RRM mutant expression plasmids display a very unusual 
localization.  Aggregates form bright, round cytoplasmic structures.  Increasing induction 
time from 4 to 18 hours results in an increase in inclusion size.  Cells often contain a 
single inclusion (Figure 13 and 14). 
S48E and ΔCTD showed similar nuclear localization after a 4-hour induction.  
Cells expressing protein show overlap of DsRed and DAPI staining.  Cytoplasmic TDP-
43 remains diffuse (Figure 13).  18-hour images of S48E show a single, large aggregate 
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overlapping, but larger in size, with the nucleus. 18-hour images of ΔCTD still show 
diffuse cytoplasmic protein with nuclear localization (Figure 14). 
3.4 TDP-43 and TDP-43 mutant Aggregation in Wild-Type and dbr1Δ Yeast 
To identify wild type and mutant TDP-43 aggregation differences in wild type 
and dbr1Δ yeast, wild type and dbr1Δ yeast containing plasmids coding for C-terminally 
DsRed tagged TDP-43 or a mutant TDP-43 on a galactose promoter were observed using 
a confocal microscope.  Deletion of the dbr1 gene previously showed prevention of 
multiple, irregular shaped aggregates (Johnson et al., 2012).  Aggregates instead formed 
round singular cytoplasmic inclusions. 
After a 4-hour induction, cells containing TDP-43 and Q331K agree with the 
previous findings in dbr1Δ yeast.  Singular round cytoplasmic inclusions are oberserved.  








Figure 12: Yeast containing DsRed on a galactose promotor. 1. Unstimulated cultures 
before and after contrast adjustment.  Background is effectively removed after lower 
contrast was set to 500. 2. Stimulated cultures before and after contrast adjustment.  
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Figure 13: Confocal imaging comparing wild type TDP-43 to 
varous mutants of TDP-43 in wild type yeast after 4 hours of 









Figure 14: Confocal imaging comparing wild type TDP-43 to 
varous mutants of TDP-43 in wild type yeast after 18 hours of 










 Figure 15: Confocal imaging comparing wild type TDP-43 to 
varous mutants of TDP-43 in dbr1Δ yeast after 4 hours of induction in 









Figure 16:  Confocal imaging comparing wild type TDP-43 to 
varous mutants of TDP-43 in dbr1Δ yeast after 18 hours of induction 








3.5 Wild Type and RRM Mutant FRAP 
RRM mutant and wild type aggregates were photobleached to observe the 
dynamics of the inclusion.  Aggregates only partly recovered by time=50 seconds (46 
seconds after photobleaching.  Over the 46 seconds, the RRM mutant aggregate 
recovered to a larger extent compared to the wild type aggregate (Figure 17).  Recovery 
of fluorescents proves diffusion of labeled TDP-43 and a dynamic state of the inclusion. 
  
		
Figure 17:  Different timepoints of FRAP experiment.  Photobleacing 







3.6 Wild Type TDP-43 Aggregation With TDP-43 Decoys 
To identify the effects of synthetic RNA on cell viability in yeast containing TDP-
43, yeast-spotting assays were performed on wild type yeast containing plasmids coding 
for C-terminally DsRed tagged TDP-43 on a galactose promoter and constitutively active 
plasmids coding for the synthetic RNA.  Cells were tested 3 different synthetic RNAs.  
The RNAs differed in number of TDP-43 binding domains (UG rich sequences).  RNAs 
contained 1, 5, or 10 binding domains.  To ensure the DsRed fluorescent protein didn’t 
have a toxic effect on the yeast, the first 6 amino acids of yeast GAPDH were linked to 
the DsRed fluorescent protein on the C-terminal.  Yeast were serially spotted on an 
auxotrophic selective plate containing glucose (expression off) or galactose (expression 
on). Spotting on a glucose plate ensured consistent spotting between all test groups and a 
baseline for no toxicity.  Spotting on a glucose plate also ensure that adding transcription 
of synthetic RNAs to the yeast doesn’t reduce cell viability.    
Yeast containing expression plasmids coding for DsRed and empty destination 
vector showed viability equal to yeast on the glucose plate (expression off).  TDP-43 and 
empty destination vector showed high levels of toxicity compared to yeast containing 
plasmids coding for DsRed and empty destination vector.   Yeast expressing TDP-43 
with X2DSH2E and X2D10SH2E showed equal levels of viability compared to yeast 





Figure 18: Yeast spotting assay comparing yeast containing TDP-43 with and 
without syntheticly designed RNA decoys. Fivefold serial dilution of yeast cells spotted 














Chapter Four: Conclusions 
4.1 Thesis Summary  
TDP-43 aggregation and cytoplasmic inclusion are hallmarks of non-familial 
ALS.  Distinct pathologies present when mutations of TDP-43 are overexpressed in S. 
cerevisiae.  Disruption of the RRM1 by two phenylalanine mutations prevents the ability 
of TDP-43 to bind RNA by eliminating the ability to form pi-pi stacking in the RRM1 
domain (Buratti et al., 2001).  Imaging of RRM shows the mutant still aggregates when 
overexpressed, but yeast spotting assays present evidence the mutation now renders the 
protein non-toxic.  These findings suggest binding and sequestering of RNAs in the cell 
result in a loss of cell viability.   
The C-terminal domain of TDP-43 proves to be important for protein aggregation.  
Two different mutations in the C-terminal domain were tested.  One mutation, Q331K 
(lysine to glutamine substitution at residue 331), disrupts the alpha helix in the C-
terminal.  This disruption of the alpha helix significantly disrupts phase separation—
stimulating the conversion to aggregates (Conicella et al., 2016).  Confocal imaging of 
Q331K shows more cytoplasmic inclusions per cell compared to wild-type TDP-43 after 
4-hour induction.  After an 18-hour induction, Q331K inclusions are larger in size than 
wild type TDP-43.  An increased proclivity to aggregate doesn’t result in decreased cell 
viability in yeast spotting assays.  Overexpression of both Q331K and wild type TDP-43 
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show similar levels of toxicity.  This result possibly stems from reaching the upper 
threshold of cytotoxicity.  Both wild type TDP-43 and Q331K show almost complete 
elimination of cell viability.  Yeast spotting assays performed with yeast containg wild 
type TDP-43 and Q331K on low copy plasmids might provide more insight on toxicity 
differences.   
Deletion of the C-terminal domain removes the “prion-like” properties of TDP-43 
while leaving the RNA binding ability and selectivity domain alone.  The truncation 
answers an interesting question about the structural influence of TDP-43’s toxicity in 
yeast.  Confocal imaging shows a decreased propensity to aggregate.  Yeast spotting 
assays show a decreased toxicity compared to wild-type TDP-43.  Aggregation of the 
protein proves to be an important aspect of the toxicity of TDP-43. Some loss of cell 
viability was seen in yeast containing the ΔCTD mutant (possibly indicating soluble 
protein bound to RNA in the cytoplasm still reduces cell viability).  
The N-terminal domain of TDP-43 creates the interface in the native dimeric 
state.  Hydrogen bonding and electrostatic forces hold this dimeric state together.  
Mutation of serine to glutamic acid at the 48th residue disrupts hydrogen bonding in the 
interface and weakens the assembly of the dimeric state (Wang et al., 2018).  Confocal 
images of S48E after 4 and 18-hour inductions differ greatly.  After 4 hours, cells 
containing S48E show large amount of nuclear protein with diffuse cytoplasmic protein.  
18-hour images show a single large aggregate overlapping, but larger in size, with the 
nucleus.  Though differences in aggregation tendencies are observed between wild type 
47 
 
TDP-43 and S48E exist, overexpression results in similar levels of toxicity.  Similar to 
the results of Q331K, yeast-spotting assays performed with yeast containg wild type 
TDP-43 and S48E on low copy plasmids might provide more insight on toxicity 
differences.   
 Preliminary RNA decoy results show present a lack of “rescue” effect by decoys.  
No difference in cell viability was observed.  So far, live cell imaging has failed to 
capture images of tagged RNAs.  JPS_1481 decoys are currently being tested.  Since 
larger UG repeat length result in a larger affinity for TDP-43 binding, the increased 
binding domain length of 12 nucleotides per binding site in JPS_1481 decoys offers 
optimism for an increased propensity to co-localize with TDP-43.  Based on RRM mutant 
toxicity data, TDP-43 binding to RNAs drives cellular toxicity (possibly by disrupting 
critical RNAs in the cytoplasm).  Introducing these synthetic RNAs, containing regions 
TDP-43 preferentially binds, offers hope to rescuing cells from TDP-43 toxicity without 
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